You can buy or sell Achaogen and other stocks, options, ETFs, and crypto commission-free!
Achaogen, Inc. Common Stock, also called Achaogen, is a biopharmaceutical company, which engages in the research, development, and commercialization of antibacterial treatments for multi-drug resistant (MDR) gram-negative infections. Read More It offers Plazomicin to treat bacterial illness, such as complicated urinary tract infection, blood stream infections, and other infections due to MDR Enterobacteriaceae. The company was founded by Nathaniel E. David in June 2002 and is headquartered in South San Francisco, CA.
South San Francisco, California
52 Week High
52 Week Low
Research And Development
Simply Wall StMar 6
What You Must Know About Achaogen, Inc.’s (NASDAQ:AKAO) Beta Value
Anyone researching Achaogen, Inc. (NASDAQ:AKAO) might want to consider the historical volatility of the share price. Volatility is considered to be a measure of risk in modern finance theory. Investors may think of volatility as falling into two main categories. The first category is company specific volatility. This can be dealt with by limiting your exposure to any particular stock. The second type is the broader market volatility, which you cannot diversify away, since it arises from macroeconomic factor...
Stock Price, News, & Analysis for Achaogen
Achaogen, Inc., a late-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial treatments against multi-drug resistant (MDR) gram-negative infections in the United States. The company is principally developing plazomicin for the treatment of serious bacterial infections, including urinary tract infections, blood stream infections, and other infections due to MDR enterobacteriaceae comprising carbapenem-resistant enterobacteriaceae. It is also involved i...
-$0.75 per share
Available Mar 28, After Hours